Alejandro Berlin1, Jure Murgic2, Ali Hosni2, Melania Pintilie2, Adriana Salcedo3, Michael Fraser4, Suzanne Kamel-Reid5, Jingbin Zhang6, Qiqi Wang6, Carolyn Ch'ng6, Samineh Deheshi6, Elai Davicioni6, Theodorus van der Kwast5, Paul C Boutros7, Robert G Bristow8, Melvin L K Chua9. 1. Princess Margaret Cancer Centre, University Health Network, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Ontario, Canada; Techna Institute, University Health Network, Ontario, Canada. Electronic address: alejandroberlin@gmail.com. 2. Princess Margaret Cancer Centre, University Health Network, Ontario, Canada. 3. Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Ontario, Canada. 4. Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Ontario, Canada. 5. Laboratory Medicine Program, University Health Network, Ontario, Canada. 6. GenomeDx Biosciences Inc., Vancouver, British Columbia, Canada. 7. Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Ontario, Canada. 8. Princess Margaret Cancer Centre, University Health Network, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Ontario, Canada; Manchester Cancer Research Centre, Manchester, United Kingdom. 9. Princess Margaret Cancer Centre, University Health Network, Ontario, Canada; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Division of Medical Sciences, National Cancer Centre Singapore, Singapore; Oncology Academic Program, Duke-NUS Medical School, Singapore.
Abstract
PURPOSE: The National Comprehensive Cancer Network (NCCN) has recently endorsed the stratification of intermediate-risk prostate cancer (IR-PCa) into favorable and unfavorable subgroups and recommend the addition of androgen deprivation therapy (ADT) to radiation therapy (RT) for unfavorable IR-PCa. Recently, more accurate prognostication was demonstrated by integrating a 22-feature genomic classifier (GC) to the NCCN stratification system. Here, we test the utility of the GC to better identify patients with IR-PCa who are sufficiently treated by RT alone. METHODS AND MATERIALS: We identified a novel cohort comprising 121 patients with IR-PCa treated with dose-escalated image guided RT (78 Gy in 39 fractions) without ADT. GC scores were derived from tumors sampled in diagnostic biopsies. Multivariable analyses, including both NCCN subclassification and GC scores, were performed for biochemical failure (prostate-specific antigen nadir + 2 ng/mL) and metastasis occurrence. RESULTS: By NCCN subclassification, 33 (27.3%) and 87 (71.9%) of men were classified as having favorable and unfavorable IR-PCa, respectively (1 case unclassifiable). GC scores were high in 3 favorable IR-PCa and low in 60 unfavorable IR-PCa. Higher GC scores, but not NCCN risk subgroups, were associated with biochemical relapse (hazard ratio, 1.36; 95% confidence interval [CI], 1.09-1.71] per 10% increase; P = .007) and metastasis (hazard ratio, 2.05; 95% CI, 1.24-4.24; P = .004). GC predicted biochemical failure at 5 years (area under the curve, 0.78; 95% CI, 0.59-0.91), and the combinatorial NCCN + GC model significantly outperformed the NCCN alone model for predicting early-onset metastasis (area under the curve for 5-year metastasis of 0.89 vs 0.86 [GC alone] vs 0.54 [NCCN alone]). CONCLUSIONS: We demonstrated the accuracy of the GC for predicting disease recurrence in IR-PCa treated with dose-escalated image guided RT alone. Our findings highlight the need to evaluate this GC in a prospective clinical trial investigating the role of ADT-RT in clinicogenomic-defined IR-PCa subgroups.
PURPOSE: The National Comprehensive Cancer Network (NCCN) has recently endorsed the stratification of intermediate-risk prostate cancer (IR-PCa) into favorable and unfavorable subgroups and recommend the addition of androgen deprivation therapy (ADT) to radiation therapy (RT) for unfavorable IR-PCa. Recently, more accurate prognostication was demonstrated by integrating a 22-feature genomic classifier (GC) to the NCCN stratification system. Here, we test the utility of the GC to better identify patients with IR-PCa who are sufficiently treated by RT alone. METHODS AND MATERIALS: We identified a novel cohort comprising 121 patients with IR-PCa treated with dose-escalated image guided RT (78 Gy in 39 fractions) without ADT. GC scores were derived from tumors sampled in diagnostic biopsies. Multivariable analyses, including both NCCN subclassification and GC scores, were performed for biochemical failure (prostate-specific antigen nadir + 2 ng/mL) and metastasis occurrence. RESULTS: By NCCN subclassification, 33 (27.3%) and 87 (71.9%) of men were classified as having favorable and unfavorable IR-PCa, respectively (1 case unclassifiable). GC scores were high in 3 favorable IR-PCa and low in 60 unfavorable IR-PCa. Higher GC scores, but not NCCN risk subgroups, were associated with biochemical relapse (hazard ratio, 1.36; 95% confidence interval [CI], 1.09-1.71] per 10% increase; P = .007) and metastasis (hazard ratio, 2.05; 95% CI, 1.24-4.24; P = .004). GC predicted biochemical failure at 5 years (area under the curve, 0.78; 95% CI, 0.59-0.91), and the combinatorial NCCN + GC model significantly outperformed the NCCN alone model for predicting early-onset metastasis (area under the curve for 5-year metastasis of 0.89 vs 0.86 [GC alone] vs 0.54 [NCCN alone]). CONCLUSIONS: We demonstrated the accuracy of the GC for predicting disease recurrence in IR-PCa treated with dose-escalated image guided RT alone. Our findings highlight the need to evaluate this GC in a prospective clinical trial investigating the role of ADT-RT in clinicogenomic-defined IR-PCa subgroups.
Authors: Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran Journal: Prostate Date: 2022-08 Impact factor: 4.012
Authors: Randy A Vince; Ralph Jiang; Daniel E Spratt; Todd M Morgan; Ji Qi; Jeffrey J Tosoian; Rebecca Takele; Felix Y Feng; Susan Linsell; Anna Johnson; Sughand Shetty; Patrick Hurley; David C Miller; Arvin George; Khurshid Ghani; Fionna Sun; Mariana Seymore; Robert T Dess; William C Jackson; Matthew Schipper Journal: Prostate Cancer Prostatic Dis Date: 2021-07-20 Impact factor: 5.554
Authors: Spyridon P Basourakos; Michael Tzeng; Patrick J Lewicki; Krishnan Patel; Bashir Al Hussein Al Awamlh; Siv Venkat; Jonathan E Shoag; Michael A Gorin; Christopher E Barbieri; Jim C Hu Journal: Front Oncol Date: 2021-05-28 Impact factor: 6.244
Authors: Felipe Couñago; Fernando López-Campos; Ana Aurora Díaz-Gavela; Elena Almagro; Esaú Fenández-Pascual; Iván Henríquez; Rebeca Lozano; Estefanía Linares Espinós; Alfonso Gómez-Iturriaga; Guillermo de Velasco; Luis Miguel Quintana Franco; Ignacio Rodríguez-Melcón; José López-Torrecilla; Daniel E Spratt; Luis Leonardo Guerrero; Juan Ignacio Martínez-Salamanca; Elia Del Cerro Journal: Cancers (Basel) Date: 2020-06-12 Impact factor: 6.639